Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study-Reference-Cited by-同舟云学术

Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study

Published:2014-12 Issue:13 Volume:15 Page:1503-1512
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Kumar Shaji K,Berdeja Jesus G,Niesvizky Ruben,Lonial Sagar,Laubach Jacob P,Hamadani Mehdi,Stewart A Keith,Hari Parameswaran,Roy Vivek,Vescio Robert,Kaufman Jonathan L,Berg Deborah,Liao Eileen,Di Bacco Alessandra,Estevam Jose,Gupta Neeraj,Hui Ai-Min,Rajkumar Vincent,Richardson Paul G

Publisher

Elsevier BV

Subject

Oncology

Reference28 articles.

1. Improved survival in multiple myeloma and the impact of novel therapies;Kumar;Blood,2008

2. Recent major improvement in long-term survival of younger patients with multiple myeloma;Brenner;Blood,2008

3. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients;Kumar;Leukemia,2014

4. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma;Richardson;Blood,2010

5. Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma;Kumar;Blood,2012

Cited by 236 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ixazomib as consolidation and maintenance versus observation in patients with relapsed multiple myeloma eligible for salvage autologous stem-cell transplantation (Myeloma XII [ACCoRD]): interim analysis of a multicentre, open-label, randomised, phase 3 trial;The Lancet Haematology;2024-09

2. Persistent cytopenias after anti-BCMA CAR T-cell therapy are associated with reduced hematopoietic activity in posttreatment bone marrows;American Journal of Clinical Pathology;2024-07-20

3. Gastrointestinal toxicities of proteasome inhibitor therapy;Journal of Cancer Research and Clinical Oncology;2024-07-05

4. Multiple myeloma: 2024 update on diagnosis, risk‐stratification, and management;American Journal of Hematology;2024-06-28

5. Twice‐weekly induction with ixazomib–lenalidomide–dexamethasone (IRd) combination followed by extended IRd consolidation and lenalidomide maintenance in transplant‐eligible patients with newly diagnosed multiple myeloma: Results of the phase 2 study IFM2014‐03;British Journal of Haematology;2024-05-29